Develops drugs for central nervous system conditions.
Jun 2026Revenue $777M/yrExpenses $963M/yr
Expected break-even Oct 2027Cash runway ≈ 4.4 years from Jun 2026
Figures by year
When will Axsome Therapeutics be profitable?
Its revenue and expense trends are projected to cross in Oct 2027. In the 12 months to Jun 2026, revenue was $777M and expenses $963M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $638M | $805M | −$167M |
| Dec 2024 | $386M | $666M | −$281M |
| Dec 2023 | $271M | $502M | −$232M |
| Dec 2022 | $50.0M | $230M | −$180M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.